We are live on
!
Find out more
FCMV
Foresite Capital Management VI Portfolio holdings
AUM
$460M
1-Year Est. Return
261.77%
This Fund
S&P 500
This Quarter
Est. Return
+25.21%
1 Year Est. Return
+261.77%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$331M
AUM Growth
+$72M
(+28%)
Cap. Flow
+$33.8M
Cap. Flow
% of AUM
10.21%
Top 10 Holdings %
Top 10 Hldgs %
94.89%
Holding
15
New
3
Increased
2
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$18.6M |
| 2 |
Natera
NTRA
|
+$14M |
| 3 |
AtaiBeckley Inc
ATAI
|
+$13M |
| 4 |
Verastem
VSTM
|
+$4.63M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$1.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$11.6M |
| 2 |
Corvus Pharmaceuticals
CRVS
|
+$2.76M |
| 3 |
RNAM
Avidity Biosciences
RNAM
|
+$1.74M |
| 4 |
CASI
CASI Pharmaceuticals
CASI
|
+$1.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$6.38B
| $92.2M | 27.88% |
2,221,474
| – | – |
|
|
RAPT
2
DELISTED
RAPT Therapeutics
RAPT
| $52.9M | 16% |
1,562,500
| – | – |
|
|
ALMS
3
Alumis Inc
ALMS
$3.44B
| $41.5M | 12.53% |
4,247,670
| – | – |
|
|
CNTA
4
DELISTED
Centessa Pharmaceuticals
CNTA
| $34.1M | 10.31% |
1,364,019
+50,000
| +4% | +$1.27M |
|
|
5
Verastem
VSTM
$539M
| $24.2M | 7.32% |
3,135,120
+520,000
| +20% | +$4.63M |
|
6
Denali Therapeutics
DNLI
$3.76B
| $16.5M | 4.99% |
1,000,000
| – | – |
|
|
7
Natera
NTRA
$36.8B
| $15.4M | 4.66% |
+67,356
| New | +$14M |
|
|
8
Agios Pharmaceuticals
AGIO
$2.17B
| $14.4M | 4.36% |
+530,000
| New | +$18.6M |
|
9
Kymera Therapeutics
KYMR
$8.82B
| $11.4M | 3.44% |
146,332
| – | – |
|
|
10
AtaiBeckley Inc
ATAI
$2.65B
| $11.2M | 3.4% |
+2,750,000
| New | +$13M |
|
|
11
Corvus Pharmaceuticals
CRVS
$1.1B
| $10.6M | 3.21% |
1,381,233
-350,000
| -20% | -$2.76M |
|
|
HNGE
12
Hinge Health
HNGE
$5.78B
| $6.27M | 1.9% |
135,000
| – | – |
|
|
AKRO
13
DELISTED
Akero Therapeutics
AKRO
| – | – |
-244,900
| Closed | -$11.6M |
|
|
CASI
14
DELISTED
CASI Pharmaceuticals
CASI
| – | – |
-979,956
| Closed | -$1.63M |
|
|
RNAM
15
DELISTED
Avidity Biosciences
RNAM
| – | – |
-40,000
| Closed | -$1.74M |
|
Similar funds
MCB
WCM
PC
PIN
FCG
GLAM
PRCP
AC
Foresite Capital Management VI's Q4 2025 Portfolio in Review
As of Q4 2025, Foresite Capital Management VI held 15 positions worth $331M, up 28% from $259M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Foresite Capital Management VI deployed $33.8M of net new capital in Q4 2025, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was Agios Pharmaceuticals: 530,000 shares worth $14.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Corvus Pharmaceuticals, an estimated $2.76M trimmed.
- Foresite Capital Management VI's largest Q4 2025 buy was Agios Pharmaceuticals: 530,000 shares worth $14.4M.
- Foresite Capital Management VI added most to Verastem in Q4 2025, an estimated $4.63M increase.
- Foresite Capital Management VI's biggest Q4 2025 reduction was Corvus Pharmaceuticals, cutting an estimated $2.76M.
- Foresite Capital Management VI fully exited Akero Therapeutics in Q4 2025, selling an estimated $11.6M.
- Foresite Capital Management VI's ten largest holdings make up 95% of its $331M portfolio in Q4 2025.
- Foresite Capital Management VI opened 3 new positions and closed 3 in Q4 2025.
- Foresite Capital Management VI's portfolio value rose 28% quarter-over-quarter to $331M.
Based on Foresite Capital Management VI's 13F filing for Q4 2025, filed 17 Feb 2026.